Browse NKAP

Summary
SymbolNKAP
NameNFKB activating protein
Aliases FLJ22626; NF kappaB activating protein; NF-kappaB activating protein; NF-kappa-B-activating protein
Chromosomal LocationXq24
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Nucleus
Domain PF06047 Ras-induced vulval development antagonist
Function

Acts as a transcriptional repressor. Plays a role as a transcriptional corepressor of the Notch-mediated signaling required for T-cell development. Also involved in the TNF and IL-1 induced NF-kappa-B activation. Associates with chromatin at the Notch-regulated SKP2 promoter.

> Gene Ontology
 
Biological Process GO:0002521 leukocyte differentiation
GO:0002573 myeloid leukocyte differentiation
GO:0002694 regulation of leukocyte activation
GO:0002696 positive regulation of leukocyte activation
GO:0006626 protein targeting to mitochondrion
GO:0006839 mitochondrial transport
GO:0007159 leukocyte cell-cell adhesion
GO:0007219 Notch signaling pathway
GO:0010821 regulation of mitochondrion organization
GO:0010822 positive regulation of mitochondrion organization
GO:0019827 stem cell population maintenance
GO:0022407 regulation of cell-cell adhesion
GO:0022409 positive regulation of cell-cell adhesion
GO:0030098 lymphocyte differentiation
GO:0030099 myeloid cell differentiation
GO:0030217 T cell differentiation
GO:0030851 granulocyte differentiation
GO:0032386 regulation of intracellular transport
GO:0032388 positive regulation of intracellular transport
GO:0033077 T cell differentiation in thymus
GO:0033157 regulation of intracellular protein transport
GO:0042110 T cell activation
GO:0045580 regulation of T cell differentiation
GO:0045582 positive regulation of T cell differentiation
GO:0045619 regulation of lymphocyte differentiation
GO:0045621 positive regulation of lymphocyte differentiation
GO:0045785 positive regulation of cell adhesion
GO:0046631 alpha-beta T cell activation
GO:0046632 alpha-beta T cell differentiation
GO:0046634 regulation of alpha-beta T cell activation
GO:0046635 positive regulation of alpha-beta T cell activation
GO:0046637 regulation of alpha-beta T cell differentiation
GO:0046638 positive regulation of alpha-beta T cell differentiation
GO:0050863 regulation of T cell activation
GO:0050865 regulation of cell activation
GO:0050867 positive regulation of cell activation
GO:0050870 positive regulation of T cell activation
GO:0051222 positive regulation of protein transport
GO:0051249 regulation of lymphocyte activation
GO:0051251 positive regulation of lymphocyte activation
GO:0070486 leukocyte aggregation
GO:0070489 T cell aggregation
GO:0070585 protein localization to mitochondrion
GO:0071425 hematopoietic stem cell proliferation
GO:0071593 lymphocyte aggregation
GO:0071594 thymocyte aggregation
GO:0072089 stem cell proliferation
GO:0072655 establishment of protein localization to mitochondrion
GO:0090316 positive regulation of intracellular protein transport
GO:0098727 maintenance of cell number
GO:1902105 regulation of leukocyte differentiation
GO:1902107 positive regulation of leukocyte differentiation
GO:1903037 regulation of leukocyte cell-cell adhesion
GO:1903039 positive regulation of leukocyte cell-cell adhesion
GO:1903214 regulation of protein targeting to mitochondrion
GO:1903533 regulation of protein targeting
GO:1903706 regulation of hemopoiesis
GO:1903708 positive regulation of hemopoiesis
GO:1903747 regulation of establishment of protein localization to mitochondrion
GO:1903749 positive regulation of establishment of protein localization to mitochondrion
GO:1903829 positive regulation of cellular protein localization
GO:1903955 positive regulation of protein targeting to mitochondrion
GO:1904951 positive regulation of establishment of protein localization
Molecular Function GO:0003682 chromatin binding
GO:0031490 chromatin DNA binding
GO:0043566 structure-specific DNA binding
Cellular Component -
> KEGG and Reactome Pathway
 
KEGG -
Reactome -
Summary
SymbolNKAP
NameNFKB activating protein
Aliases FLJ22626; NF kappaB activating protein; NF-kappaB activating protein; NF-kappa-B-activating protein
Chromosomal LocationXq24
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between NKAP and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.
Summary
SymbolNKAP
NameNFKB activating protein
Aliases FLJ22626; NF kappaB activating protein; NF-kappaB activating protein; NF-kappa-B-activating protein
Chromosomal LocationXq24
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of NKAP in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolNKAP
NameNFKB activating protein
Aliases FLJ22626; NF kappaB activating protein; NF-kappaB activating protein; NF-kappa-B-activating protein
Chromosomal LocationXq24
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of NKAP in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.0710.709
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.3390.848
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.1280.925
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.0380.884
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.040.979
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.0410.984
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.0880.758
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-0.0950.941
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.0460.973
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.3790.75
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.4610.803
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.1160.0312
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of NKAP in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14177.15.91.21
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 103100101
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 41407.1-7.11
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277311.1011.10.0181
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275911.1011.10.0286
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21174.85.9-1.11
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13117.79.1-1.41
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38272.602.61
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22134.504.51
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolNKAP
NameNFKB activating protein
Aliases FLJ22626; NF kappaB activating protein; NF-kappaB activating protein; NF-kappa-B-activating protein
Chromosomal LocationXq24
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of NKAP. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolNKAP
NameNFKB activating protein
Aliases FLJ22626; NF kappaB activating protein; NF-kappaB activating protein; NF-kappa-B-activating protein
Chromosomal LocationXq24
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of NKAP. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by NKAP.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolNKAP
NameNFKB activating protein
Aliases FLJ22626; NF kappaB activating protein; NF-kappaB activating protein; NF-kappa-B-activating protein
Chromosomal LocationXq24
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of NKAP. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolNKAP
NameNFKB activating protein
Aliases FLJ22626; NF kappaB activating protein; NF-kappaB activating protein; NF-kappa-B-activating protein
Chromosomal LocationXq24
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of NKAP expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolNKAP
NameNFKB activating protein
Aliases FLJ22626; NF kappaB activating protein; NF-kappaB activating protein; NF-kappa-B-activating protein
Chromosomal LocationXq24
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between NKAP and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolNKAP
NameNFKB activating protein
Aliases FLJ22626; NF kappaB activating protein; NF-kappaB activating protein; NF-kappa-B-activating protein
Chromosomal LocationXq24
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting NKAP collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.